Raymond James resumed coverage of Harmony Biosciences with an Outperform rating and $40 price target The Citizen Petition was dismissed, removing an overhang on the stock, and the firm sees upside opportunities along with the recent Wakix label expansion into pediatrics, and the upcoming Idiopathic Hypersomnia filing, the analyst tells investors in a research note. Raymond James adds that the outlook for Wakix sales remains strong, and the company continues to advance the recently expanded clinical pipeline.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY: